Mathai Mammen - 11 Jun 2024 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Reporting relationship: Director
Issuer ticker: TXG
Reported as of: 11 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2024, 16:22:45 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Eric S. Whitaker, as Attorney-in-Fact for Mathai Mammen

Key filing fact

Mathai Mammen filed Form 4 for 10x Genomics, Inc. (TXG) on 13 Jun 2024.

Key facts

This page summarizes Mathai Mammen's Form 4 filing for 10x Genomics, Inc. (TXG).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Jun 2024, 16:22.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TXG transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +8,649
Change %: +5%
Price: $0.000000
Shares after: 180,259
Date: 11 Jun 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2024, subject to the Reporting Person continuing as a service provider through each such date.